PMID- 29614624
OWN - NLM
STAT- MEDLINE
DCOM- 20181001
LR  - 20181001
IS  - 1875-8592 (Electronic)
IS  - 1574-0153 (Linking)
VI  - 22
IP  - 1
DP  - 2018
TI  - Baicalein suppresses non small cell lung cancer cell proliferation, invasion and 
      Notch signaling pathway.
PG  - 13-18
LID - 10.3233/CBM-170673 [doi]
AB  - BACKGROUND: Baicalein is an important Chinese herbal medicine and has multiple 
      pharmacological activities. However, the biological mechanisms of the anti-tumor 
      effects of Baicalein on non small cell lung cancer (NSCLC) still need to be 
      understood. METHODS: Human NSCLC A549 and H1299 cells were pretreated with 
      Baicalein or DMSO. Cells viability and transwell cell invasion assays were 
      performed to assess cell proliferation and invasion. QRT-PCR assay was used to 
      analyze mRNA expression levels of Twist1, E-cadhertin, Vimentin, Notch1 and 
      hes-1. Western blot analysis was also performed to determine protein expression. 
      RESULTS: In the study, we found that Baicalein had a significantly inhibited 
      effect on proliferation ability of A549 and H1299 cells. Cells treated with 
      Baicalein showed a down-regulated expression of CyclinD1 and CDK1 in A549 and 
      H1299 cells. Furthermore, we found that Baicalein significantly inhibited cell 
      invasion and Epithelial-Mesenchymal Transition (EMT) by up-regulating the mRNA 
      and protein expression of E-cadherin and down-regulated the Twist1 and Vimentin 
      expression, Moreover, Treatment of Baicalein down-regulated Notch1 and hes-1 
      expression in A549 and H1299 cells, which indicated that Baicalein could suppress 
      the Notch signaling pathway. CONCLUSION: Our studies suggest that Baicalein may 
      be a potential phytochemical flavonoid for therapeutics of NSCLC and serve as a 
      molecular target for NSCLC.
FAU - Su, Guangfeng
AU  - Su G
AD  - Department of Thoracic Surgery, the Affiliated Hospital of Shandong University of 
      Traditional Chinese Medicine, Jinan 250014, Shandong, China.
AD  - Department of Thoracic Surgery, the Affiliated Hospital of Shandong University of 
      Traditional Chinese Medicine, Jinan 250014, Shandong, China.
FAU - Chen, Hao
AU  - Chen H
AD  - Department of Pharmacy, Qilu Hospital of Shandong University, Jinan 250012, 
      Shandong, China.
AD  - Department of Thoracic Surgery, the Affiliated Hospital of Shandong University of 
      Traditional Chinese Medicine, Jinan 250014, Shandong, China.
FAU - Sun, Xinhua
AU  - Sun X
AD  - Department of Surgery, Boshan District Hospital of Traditional Chinese Medicine, 
      Zibo 255200, Shandong, China.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Cancer Biomark
JT  - Cancer biomarkers : section A of Disease markers
JID - 101256509
RN  - 0 (Antioxidants)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Flavanones)
RN  - 0 (Receptor, Notch1)
RN  - 49QAH60606 (baicalein)
SB  - IM
MH  - Antioxidants/pharmacology/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
MH  - Cell Proliferation
MH  - Drugs, Chinese Herbal/pharmacology/*therapeutic use
MH  - Epithelial-Mesenchymal Transition/*genetics
MH  - Flavanones/pharmacology/*therapeutic use
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Neoplasm Invasiveness
MH  - Receptor, Notch1/*metabolism
MH  - Signal Transduction
OTO - NOTNLM
OT  - Baicalein
OT  - cell proliferation
OT  - epithelial-mesenchymal transition
OT  - non small cell lung cancer
EDAT- 2018/04/05 06:00
MHDA- 2018/10/03 06:00
CRDT- 2018/04/05 06:00
PHST- 2018/04/05 06:00 [pubmed]
PHST- 2018/10/03 06:00 [medline]
PHST- 2018/04/05 06:00 [entrez]
AID - CBM170673 [pii]
AID - 10.3233/CBM-170673 [doi]
PST - ppublish
SO  - Cancer Biomark. 2018;22(1):13-18. doi: 10.3233/CBM-170673.